Aurora-A kinase: a novel target of cellular immunotherapy for leukemia

作者：Ochi Toshiki; Fujiwara Hiroshi; Suemori Koichiro; Azuma Taichi; Yakushijin Yoshihiro; Hato Takaaki; Kuzushima Kiyotaka; Yasukawa Masaki^*

来源：Blood, 2009, 113(1): 66-74.

DOI：10.1182/blood-2008-06-164889

Aurora-A kinase (Aur-A) is a member of the serine/threonine kinase family that regulates the cell division process, and has recently been implicated in tumorigenesis. In this study, we identified an antigenic 9-amino-acid epitope (Aur-A(207-215): YLILEYAPL) derived from Aur-A capable of generating leukemia-reactive cytotoxic T lymphocytes (CTLs) in the context of HLA-A*0201. The synthetic peptide of this epitope appeared to be capable of binding to HLA-A*2402 as well as HLA-A*0201 molecules. Leukemia cell lines and freshly isolated leukemia cells, particularly chronic myelogenous leukemia (CML) cells, appeared to express Aur-A abundantly. Aur-A-specific CTLs were able to lyse human leukemia cell lines and freshly isolated leukemia cells, but not normal cells, in an HLA-A*0201 restricted manner. Importantly, Aur-A specific CTLs were able to lyse CD34(+) CML progenitor cells but did not show any cytotoxicity against normal CD34(+) hematopoietic stem cells. The tetramer assay revealed that the Aur-A(207-215) epitope-specific CTL precursors are present in peripheral blood of HLA-A*0201-positive and HLA-A*2402 positive patients with leukemia, but not in healthy individuals. Our results indicate that cellular immunotherapy targeting Aur-A is a promising strategy for treatment of leukemia. (Blood. 2009; 113: 66-74)

• 出版日期2009-1-1